Stockscreener 앱 받기
0.00
100.00%
-0.55
Marinus Pharmaceuticals Inc 주식(MRNS)의 최신 뉴스
Developmental and Epileptic Encephalopathies Treatment - openPR
Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com - Armenian Reporter
MRNS LAWSUIT ALERT: Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMRNS - ACCESS Newswire
Long-Term Investors in Marinus Pharmaceuticals, Inc. (NASDAQ: - openPR
StockNews.com Initiates Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS) - Armenian Reporter
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Shareholders - ACCESS Newswire
Class Action Filed Against Marinus Pharmaceuticals, Inc. (MRNS) Seeking Recovery for Investors – Contact Levi & Korsinsky - ACCESS Newswire
Marinus Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Class Action Filed Against Marinus Pharmaceuticals, Inc. (MRNS) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Marinus pharmaceuticals director sells shares for $864 - MSN
Marinus Pharmaceuticals director sells shares worth $869 - MSN
Marinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stock - MSN
Tuberous Sclerosis Complex Therapeutics Market Size Report - openPR
IMMINENT MRNS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com - Defense World
Marinus Pharmaceuticals (NASDAQ:MRNS) Acquisition Completed by Immedica Pharma AB - Defense World
Marinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stock By Investing.com - Investing.com UK
Immedica Pharma Completes Acquisition of Marinus Pharmaceuticals - TipRanks
Make Informed Decisions with Marinus Pharmaceuticals Inc (MRNS) Stock Updates - The News Heater
Taking on analysts’ expectations and winning: Marinus Pharmaceuticals Inc (MRNS) - SETE News
Marinus Pharmaceuticals, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your RightsMRNS - ACCESS Newswire
Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) should contact Levi & Korsinsky about pending Class ActionMRNS - ACCESS Newswire
MARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Marinus Pharmaceuticals, Inc. Investors of Upcoming Deadline - ACCESS Newswire
Morgan Stanley's Strategic Acquisition of Marinus Pharmaceuticals Shares - GuruFocus.com
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Average Recommendation of “Hold” by Brokerages - Defense World
JPMorgan Chase & Co. Buys 126,752 Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Defense World
Vanguard Group Inc Reduces Holdings in Marinus Pharmaceuticals I - GuruFocus.com
MRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
UPCOMING MRNS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Shares Sold by Assenagon Asset Management S.A. - Defense World
Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis - MarketBeat
Marinus pharmaceuticals director sells shares for $864 By Investing.com - Investing.com Canada
Immedica to buy Marinus Pharmaceuticals for $151m - MSN
Fragile X Syndrome Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Novartis, Neuren Pharma, Roche, Seaside Therapeutics, Inc., Marinus Pharma, Lysogene - Barchart
Fragile X Syndrome Market Predicted to See Upsurge Through 2034, - openPR
$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of AE, MRNS, SASR, ROIC to Take Action - The Malaysian Reserve
Marinus plummets 78% as phase 3 interim analysis of ganaxolone disappoints - MSN
Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know - MSN
Beryl Capital Management LLC Acquires Significant Stake in Marin - GuruFocus.com
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates MRNS, RHE, SSY, CTV on Behalf of Shareholders - Morningstar
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Marinus Pharmaceuticals, Inc.MRNS - Kilgore News Herald
Immedica Pharma AB’s Acquisition of Marinus Pharmaceuticals - Global Legal Chronicle
MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc.MRNS - Business Wire
Immedica acquires Marinus in $151 million deal - The Pharma Letter
Marinus Therapeutics in Radnor Acquired by Swedish Company - MSN
StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS) - Defense World
0.22%
0.27%
자본화:
|
볼륨(24시간):